European association of urology guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ)-2019 update
M Babjuk, M Burger, EM Compérat, P Gontero… - European urology, 2019 - Elsevier
Context This overview presents the updated European Association of Urology (EAU)
guidelines for non–muscle-invasive bladder cancer (NMIBC), TaT1, and carcinoma in situ …
guidelines for non–muscle-invasive bladder cancer (NMIBC), TaT1, and carcinoma in situ …
Updates in the eighth edition of the tumor-node-metastasis staging classification for urologic cancers
GP Paner, WM Stadler, DE Hansel, R Montironi… - European urology, 2018 - Elsevier
Abstract The Tumor-Node-Metastasis (TNM) classification on cancer staging, jointly
developed by the American Joint Commission on Cancer (AJCC) and the Union for …
developed by the American Joint Commission on Cancer (AJCC) and the Union for …
EAU guidelines on non–muscle-invasive urothelial carcinoma of the bladder: update 2016
M Babjuk, A Böhle, M Burger, O Capoun, D Cohen… - European urology, 2017 - Elsevier
Abstract Context The European Association of Urology (EAU) panel on Non–muscle-
invasive Bladder Cancer (NMIBC) released an updated version of the guidelines on Non …
invasive Bladder Cancer (NMIBC) released an updated version of the guidelines on Non …
Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO guideline
SS Chang, SA Boorjian, R Chou, PE Clark… - The Journal of …, 2016 - auajournals.org
Purpose: Although associated with an overall favorable survival rate, the heterogeneity of
non-muscle invasive bladder cancer (NMIBC) affects patients' rates of recurrence and …
non-muscle invasive bladder cancer (NMIBC) affects patients' rates of recurrence and …
Bladder cancer, version 5.2017, NCCN clinical practice guidelines in oncology
PE Spiess, N Agarwal, R Bangs, SA Boorjian… - Journal of the National …, 2017 - jnccn.org
This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines)
for Bladder Cancer focuses on systemic therapy for muscle-invasive urothelial bladder …
for Bladder Cancer focuses on systemic therapy for muscle-invasive urothelial bladder …
Impact of molecular subtyping and immune infiltration on pathological response and outcome following neoadjuvant pembrolizumab in muscle-invasive bladder …
A Necchi, D Raggi, A Gallina, JS Ross, E Farè… - European urology, 2020 - Elsevier
Abstract Background The PURE-01 study (NCT02736266) evaluated the use of
pembrolizumab before radical cystectomy (RC) in muscle-invasive bladder cancer (MIBC) …
pembrolizumab before radical cystectomy (RC) in muscle-invasive bladder cancer (MIBC) …
Prognostic and prediction tools in bladder cancer: a comprehensive review of the literature
Context This review focuses on risk assessment and prediction tools for bladder cancer
(BCa). Objective To review the current knowledge on risk assessment and prediction tools to …
(BCa). Objective To review the current knowledge on risk assessment and prediction tools to …
The health economics of bladder cancer: an updated review of the published literature
C Yeung, T Dinh, J Lee - Pharmacoeconomics, 2014 - Springer
The purpose of this paper is to provide a current view of the economic burden of bladder
cancer, with a focus on the cost effectiveness of available interventions. This review updates …
cancer, with a focus on the cost effectiveness of available interventions. This review updates …
Multiparametric MRI of the bladder: inter-observer agreement and accuracy with the Vesical Imaging-Reporting and Data System (VI-RADS) at a single reference …
G Barchetti, G Simone, I Ceravolo, V Salvo, R Campa… - European …, 2019 - Springer
Objectives To evaluate accuracy and inter-observer variability using Vesical Imaging-
Reporting and Data System (VI-RADS) for discrimination between non-muscle invasive …
Reporting and Data System (VI-RADS) for discrimination between non-muscle invasive …
Pathologic downstaging is a surrogate marker for efficacy and increased survival following neoadjuvant chemotherapy and radical cystectomy for muscle-invasive …
R Rosenblatt, A Sherif, E Rintala, R Wahlqvist, A Ullén… - European urology, 2012 - Elsevier
BACKGROUND: Characterising responders to neoadjuvant chemotherapy (NAC) is
important to minimise overtreatment and the unnecessary delay of definitive treatment of …
important to minimise overtreatment and the unnecessary delay of definitive treatment of …